Norges Bank
ITOS

Norges Bank’s iTeos Therapeutics ITOS Stock Holding History

Norges Bank’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-52,500
Closed -$1.69M – 2113
2022
Q1 		$1.69M Hold
52,500
– – ﹤0.01% 2000
2021
Q4 		$2.44M Buy
+52,500
New +$1.75M ﹤0.01% 2013
2020
Q4 		– Sell
-53,000
Closed -$1.31M – 2137
2020
Q3 		$1.31M Buy
+53,000
New +$1.43M ﹤0.01% 2007

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Norges Bank's ITOS Position: Q2 2022 in Review

Norges Bank sold out of iTeos Therapeutics (ITOS) in Q2 2022, closing a stake of 52,500 shares — an estimated $1.69M sold.

Norges Bank first reported a position in ITOS in Q3 2020 and held it in 3 quarters. The position peaked at $2.44M in Q4 2021. 152 funds tracked by Wall St. Rank hold ITOS as of Q2 2022.

  • Norges Bank reported no remaining iTeos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Norges Bank sold 52,500 iTeos Therapeutics shares in Q2 2022, an estimated $1.69M.
  • Norges Bank first reported a position in iTeos Therapeutics in Q3 2020 and held it in 3 quarters.
  • Norges Bank's iTeos Therapeutics position peaked at $2.44M in Q4 2021.
  • 152 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.